Fintel reports that on February 20, 2026, Barclays initiated coverage of Biogen (NasdaqGS:BIIB) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 1.69% Upside
As of February 4, 2026, the average one-year price target for Biogen is $195.32/share. The forecasts range from a low of $144.43 to a high of $273.00. The average price target represents an increase of 1.69% from its latest reported closing price of $192.08 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Biogen is 10,433MM, an increase of 5.48%. The projected annual non-GAAP EPS is 15.00.
What is the Fund Sentiment?
There are 1,551 funds or institutions reporting positions in Biogen. This is an decrease of 129 owner(s) or 7.68% in the last quarter. Average portfolio weight of all funds dedicated to BIIB is 0.15%, an increase of 0.37%. Total shares owned by institutions increased in the last three months by 2.95% to 150,302K shares. 
The put/call ratio of BIIB is 0.75, indicating a bullish outlook.
What are Other Shareholders Doing?
Primecap Management holds 14,758K shares representing 10.06% ownership of the company. In its prior filing, the firm reported owning 14,955K shares , representing a decrease of 1.33%. The firm increased its portfolio allocation in BIIB by 22.54% over the last quarter.
VPMCX - Vanguard PRIMECAP Fund Investor Shares holds 9,004K shares representing 6.14% ownership of the company. In its prior filing, the firm reported owning 9,009K shares , representing a decrease of 0.06%. The firm decreased its portfolio allocation in BIIB by 12.30% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 4,715K shares representing 3.21% ownership of the company. In its prior filing, the firm reported owning 4,631K shares , representing an increase of 1.78%. The firm decreased its portfolio allocation in BIIB by 16.63% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 4,367K shares representing 2.98% ownership of the company. No change in the last quarter.
Geode Capital Management holds 4,199K shares representing 2.86% ownership of the company. In its prior filing, the firm reported owning 4,069K shares , representing an increase of 3.11%. The firm decreased its portfolio allocation in BIIB by 33.11% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
